Home › NDC Lookup › RxCUI directory › RxCUI 261361

Cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] — RxCUI 261361

RxNorm drug concept · Semantic branded drug
RxCUI 261361 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI261361
Official nameCevimeline hydrochloride 30 MG Oral Capsule [Evoxac]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEvoxac 30 MG Oral Capsule
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cevimeline: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Your Sjögren's Syndrome causes your immune system to damage the glands that make saliva. Cevimeline steps in by directly activating the 'on switches' on those glands — called musca...
  • What is cevimeline actually doing for my dry mouth?
  • Taking it on an empty stomach gets it into your system a little faster and gives a slightly higher peak level. Food slows things down a bit and lowers the peak level. Either way is...
  • Should I take it with food or on an empty stomach?
📖 Read our full Cevimeline guide →

🕸️ Concept Web — How Cevimeline hydrochloride 30 MG Oral Capsule [Evo... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cevimeline hydrochloride 30 MG Oral Capsule [Evoxac] RxCUI 261361

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Cevimeline 44281
    • Cevimeline hydrochloride 260036
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Evoxac 261514
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cevimeline Oral Capsule 378855
    • Cevimeline hydrochloride Oral Capsule 2648307
    • Cevimeline Oral Product 1161241
    • Cevimeline Pill 1161242
    • Cevimeline hydrochloride Oral Product 2662955
    • Cevimeline hydrochloride Pill 2662390
    • Cevimeline Oral Capsule [Evoxac] 366528
    • Cevimeline hydrochloride Oral Capsule [Evoxac] 2657808
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cevimeline hydrochloride 30 MG Oral Capsule SCD · 309140
  • Cevimeline hydrochloride 30 MG SCDC · 2606838
  • Cevimeline Oral Capsule SCDF · 378855
  • Cevimeline hydrochloride Oral Capsule SCDFP · 2648307
  • Cevimeline Oral Product SCDG · 1161241
  • Cevimeline Pill SCDG · 1161242
  • Cevimeline hydrochloride Oral Product SCDGP · 2662955
  • Cevimeline hydrochloride Pill SCDGP · 2662390

Brand-Name Concepts

  • Cevimeline hydrochloride 30 MG [Evoxac] SBDC · 2606840
  • Cevimeline Oral Capsule [Evoxac] SBDF · 366528
  • Cevimeline hydrochloride Oral Capsule [Evoxac] SBDFP · 2657808
  • Evoxac Oral Product SBDG · 1171819
  • Evoxac Pill SBDG · 1171820
  • Evoxac BN · 261514

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 261361 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00713-0883-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0713-0883-01) Evoxac Cosette Pharmaceuticals, Inc. 2022-09-01
Observed labelers: Cosette Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$8.5909
Range $8.5909–$8.5909 · middle 50% $8.5909–$8.5909 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.